PMID- 24065789
OWN - NLM
STAT- MEDLINE
DCOM- 20131210
LR  - 20221207
IS  - 1939-327X (Electronic)
IS  - 0012-1797 (Print)
IS  - 0012-1797 (Linking)
VI  - 62
IP  - 10
DP  - 2013 Oct
TI  - Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered 
      glucose load in humans.
PG  - 3324-8
LID - 10.2337/db13-0604 [doi]
AB  - Inhibitors of sodium-glucose cotransporter 2 (SGLT2) are a novel class of 
      antidiabetes drugs, and members of this class are under various stages of 
      clinical development for the management of type 2 diabetes mellitus (T2DM). It is 
      widely accepted that SGLT2 is responsible for >80% of the reabsorption of the 
      renal filtered glucose load. However, maximal doses of SGLT2 inhibitors fail to 
      inhibit >50% of the filtered glucose load. Because the clinical efficacy of this 
      group of drugs is entirely dependent on the amount of glucosuria produced, it is 
      important to understand why SGLT2 inhibitors inhibit <50% of the filtered glucose 
      load. In this Perspective, we provide a novel hypothesis that explains this 
      apparent puzzle and discuss some of the clinical implications inherent in this 
      hypothesis.
FAU - Abdul-Ghani, Muhammad A
AU  - Abdul-Ghani MA
AD  - Division of Diabetes, University of Texas Health Science Center at San Antonio, 
      San Antonio, Texas.
FAU - DeFronzo, Ralph A
AU  - DeFronzo RA
FAU - Norton, Luke
AU  - Norton L
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Diabetes
JT  - Diabetes
JID - 0372763
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (SLC5A1 protein, human)
RN  - 0 (SLC5A2 protein, human)
RN  - 0 (Slc5a1 protein, mouse)
RN  - 0 (Slc5a2 protein, mouse)
RN  - 0 (Sodium-Glucose Transporter 1)
RN  - 0 (Sodium-Glucose Transporter 2)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - 0 (hemoglobin A1c protein, human)
SB  - IM
MH  - Animals
MH  - Diabetes Mellitus, Type 2/drug therapy/*metabolism
MH  - Drug Therapy, Combination
MH  - Glycated Hemoglobin/metabolism
MH  - Glycosuria/drug therapy/*metabolism
MH  - Humans
MH  - Hyperglycemia/drug therapy/*metabolism
MH  - Hypoglycemic Agents/*pharmacology
MH  - Insulin/therapeutic use
MH  - Kidney/metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Sodium-Glucose Transporter 1/*antagonists & inhibitors
MH  - Sodium-Glucose Transporter 2
MH  - *Sodium-Glucose Transporter 2 Inhibitors
PMC - PMC3781482
EDAT- 2013/09/26 06:00
MHDA- 2013/12/16 06:00
PMCR- 2014/10/01
CRDT- 2013/09/26 06:00
PHST- 2013/09/26 06:00 [entrez]
PHST- 2013/09/26 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2014/10/01 00:00 [pmc-release]
AID - 62/10/3324 [pii]
AID - 0604 [pii]
AID - 10.2337/db13-0604 [doi]
PST - ppublish
SO  - Diabetes. 2013 Oct;62(10):3324-8. doi: 10.2337/db13-0604.